Stock Events

Stock Events

Sprint Bioscience AB 

€0.2700
0
-€0.00-0.74% Monday 15:31

Statistics

Day High
0.277
Day Low
0.266
52W High
0.407
52W Low
0.0334
Volume
-
Avg. Volume
-
Mkt Cap
28.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26AugExpected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

55.29%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
15.39MRevenue
8.51MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.ST
Mkt Cap2.59T
AstraZeneca competes in the pharmaceutical and biotechnology industry focusing on the discovery and development of drugs, similar to Sprint Bioscience.
Novartis
NVS
Mkt Cap304.1B
Novartis is a global healthcare company that operates in the same therapeutic areas as Sprint Bioscience, making them direct competitors in drug development.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is involved in the development and manufacturing of health care products including innovative medicines and vaccines, overlapping with Sprint Bioscience's market.
Merck
MRK
Mkt Cap370.89B
Merck operates in the pharmaceutical industry, focusing on drug development and therapies, directly competing with Sprint Bioscience in the oncology and metabolic diseases sector.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to those targeted by Sprint Bioscience, including cancer treatments.
AMGEN
AMGN
Mkt Cap236.38B
Amgen focuses on human therapeutics and operates in the same biotechnology sector as Sprint Bioscience, particularly in innovative drug development.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb is a global biopharmaceutical company whose areas of research include cancer, a key focus area for Sprint Bioscience, making them competitors.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company develops and markets pharmaceutical products for global markets, competing with Sprint Bioscience in the areas of drug discovery and oncology.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG engages in the pharmaceuticals and diagnostics business, directly competing with Sprint Bioscience in the field of oncology research and drug development.
Sanofi
SNY
Mkt Cap106.01B
Sanofi operates globally in pharmaceuticals, focusing on therapeutic solutions similar to Sprint Bioscience, including treatments for chronic diseases and cancer.

About

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
Show more...
CEO
Johan Emilsson
Employees
30
Country
Sweden
ISIN
SE0006343745
WKN
000A14NY2

Listings

ST
SE
SPRINT-BTA.ST
STU
DE
5JA1.STU
MU
DE
5JA1.MU
F
DE
5JA1.F

0 Comments

Share your thoughts

FAQ

What is Sprint Bioscience AB stock price today?▼
The current price of 5JA1.STU is €0.27 EUR — it has decreased by -0.74% in the past 24 hours. Watch Sprint Bioscience AB stock price performance more closely on the chart.
What is Sprint Bioscience AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Sprint Bioscience AB stocks are traded under the ticker 5JA1.STU.
Is Sprint Bioscience AB stock price growing?▼
5JA1.STU stock has fallen by -1.82% compared to the previous week, the month change is a -9.7% fall, over the last year Sprint Bioscience AB has showed a +599.48% increase.
What is Sprint Bioscience AB market cap?▼
Today Sprint Bioscience AB has the market capitalization of 28.49M
What is Sprint Bioscience AB revenue for the last year?▼
Sprint Bioscience AB revenue for the last year amounts to 15.39M EUR.
What is Sprint Bioscience AB net income for the last year?▼
5JA1.STU net income for the last year is 8.51M EUR.
How many employees does Sprint Bioscience AB have?▼
As of September 08, 2026, the company has 30 employees.
In which sector is Sprint Bioscience AB located?▼
Sprint Bioscience AB operates in the Health & Wellness sector.
When did Sprint Bioscience AB complete a stock split?▼
The last stock split for Sprint Bioscience AB was on October 29, 2019 with a ratio of 15:14.
Where is Sprint Bioscience AB headquartered?▼
Sprint Bioscience AB is headquartered in Huddinge, Sweden.